The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

While Novo Nordisk’s CEO Lars Fruergaard Jørgensen has defended the high U.S. prices of the company’s blockbuster drugs, ...

Should he make it through the nomination process, Kennedy plans to follow Trump’s mandate to remove “corruption” from HHS-led ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other ...

open image in gallery A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, (REUTERS/Hollie Adams/File Photo ...

Novo Nordisk, Eli Lilly, Viking Therapeutics and more are publishing promising trial results. In the race to find Ozempic 2.0, a few stand-outs are emerging. While GLP-1 drugs have paved the way ...